Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Xoma Technology Ltd.

Xiaofeng Lu

Bao-lu Chen

Augustus O Okhamafe

Li Long

Mohammad Luqman

Asha Yabannavar

Sang Hoon Lee

Kidisti Araya

Isabel Zaror

Deborah Hurst

Bao-Lu Chen

Mohammed Luqman

Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.

Antagonist anti-CD40 antibody pharmaceutical compositions

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

Antagonist anti-CD40 antibodies

Growing community of inventors

Fremont, CA, United States of America

Xiaofeng Lu